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AIM OF THE STUDY 
 
 
 
1.  To determine the effect of HAART on CD4+ T cell count 
in patients with proven Adult HIV disease 
 
2.  To determine the sex wise change in CD4 count in 
patients receiving HAART therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
The dreadly disease Acquired Immune Deficieny Syndrome  
( AIDS ) appeared first around 1970s 11. The disease had not been 
recognized until in early 80s when the syndrome of immune deficiency 
was found to be widely prevalent among homosexuals and IV drug 
abusers.  
 
Later the cause was found to be a virus and was named 
Lymphadenopathy Associated Virus 22,39. Then around 1980 the virus 
was renamed as Human Immune Deficiency Virus (HIV).  
 
The first case of this disease was reported in 1980, three years 
after which the disease was named as AIDS. Prior to that the syndrome 
had several names around the world. Early cases were reported from 
USA and subsequently the disease started spreading to Africa, Europe 
and Asia. 
 
The first article on AIDS was published in 1981 authored by 
Michael Gottleib 6 . The article reported about the unusual infection of 
Pnemocystis carinii among IV drug abusers. The hunt for the HIV 
etiology has grown until the etiologic agent HIV belonging to Lentivirus 
was found. 
 
The discovery of HIV was a milestone in the history of AIDS. 
Later on elaborate research and studies were conducted and the impact 
of HIV on human immune system were revealed.  
One of the vastly studied materials is the destruction of CD4+ T 
lymphocytes by HIV , a key factor in the pathogenesis  
of the disease 1,2,3,59. 
 
The CD4 helper Cells play a major role in the body’s immune 
system. The CD4 cells are undoubtedly much reduced in number with 
advanced disease and this correlation of CD4 cells and AIDS 
progression have been studied elaborately by researchers 41. 
 
Nowadyays the disease progression and the emergence of 
opportunistic infections are predicted by CD4 T helper cell counts. 
The CD4 cells help to recognise the foreign agents and with the help of 
other T cell lineages tend to contain the infection and eliminate the 
infective agents. 
 
By destroying the CD4 cells the HIV gain access to the body 
without any resistance if at all and cause a varied syndrome. Many of 
the studies have shown an inverse relationship with CD4 cells and viral 
load 26,31. 
 
The CD4 counts are the predictors of disease progression and to 
plan the necessary treatment even though there are other parameters 
available. 
 
The antiretroviral drugs by eliminating the virions tend to 
increase the CD4 cells indirectly and this has been proved to a  large 
extent. The invention of HAART has promising effects in modulating 
the CD4 counts and decreasing the incidence of opportunistic infections 
especially Tuberculosis in our country. 
  
REVIEW OF LITERATURE 
 
 
AIDS is a syndrome of diseases following infection with HIV I and 
or HIV II. HIV is a Retrovirus belonging to the family of Lentivirus 
And formerly called as Human Lymphotrophic Virus. The replication 
of the virus occurs predominantly in the lymphatic system.the crucial 
step in viral invasion is the ligandic attachment of the virion to the CD4 
cell receptors using surface glycoproteins, causing a deficient immune 
system rendering the patient more susceptible to opportunistic 
infections which is a hallmark of AIDS. The Antiretroviral drugs 
decrease the viral load and increase the CD4 count 
 
STRUCTURE OF HIV 
 
Using electron microscopy, HIV-1 and HIV-2 resemble each other 
strikingly. However, they differ with regard to the molecular weight of 
their proteins, as well as having differences in their accessory genes. 
Both HIV-1 and HIV-2 replicate in CD4+ T-cells. 
 
HIV-1 viral particles have a diameter of 100 nm and are 
surrounded by a lipoprotein membrane. Each viral particle contains 72 
glycoprotein complexes, which are integrated into this lipid membrane, 
and are each composed of trimers of an external glycoprotein gp120 
and a transmembrane spanning protein gp41. The bonding between 
gp120 and gp41 is only loose and therefore gp120 may be shed 
spontaneously within the local environment 51.  
 
  
 
Glycoprotein gp120 may also be detected in theserum (Oh 1992) 
as well as within the lymphatic tissue of HIV-infected patients(Sunila 
1997). During the process of budding, the virus may also incorporate 
different host proteins from the membrane of the host cell into its 
lipoprotein layer, such as HLA class I and II proteins, or adhesion 
proteins such as ICAM-1 that may facilitate adhesion to other target 
cells. 
 
The p24 core antigen contains two copies of HIV-1 RNA. The 
HIV-1 RNA is part of a protein-nucleic acid complex, which is 
composed of the nucleoprotein p7 and the reverse transcriptase p66 
(RT) 51. The viral particle contains all the enzymatic equipment that is 
necessary for replication: a reverse transcriptase (RT), an integrase p32 
and a protease p11  
 
Most replication competent retroviruses depend on three genes: 
gag, pol and env: gag means group-antigen., pol represents polymerase 
and env is for envelope 25. The classical structural scheme of a retroviral 
genome is 5.LTR-gag-pol-env-LTR 3.. The LTR (long terminal region) 
 
The gag and env genes code for the nucleocapsid and the 
glycoproteins of the viral membrane; the pol gene codes for the reverse  
transcriptase and other enzymes. The accessory genes, nef, tat and rev, 
are all produced early in the viral replicationcycle. 
 
 
 Nef may induce downregulation of CD4 (Aiken 1994) and HLA 
class I molecules (Collins 1998) from the surface of HIV-1-infected cells, 
which may represent an important escape mechanism for the virus to 
evade an attack mediated by cytotoxic CD8+ T-cells and to avoid 
recognition by CD4+ T-cells. 
 
Vpr seems to be essential for viral replication in non-dividing cells 
such as macrophages. Vpu is important for the virus .budding. process 
Vif-deficient HIV-1 isolates do not replicate in CD4+ T-cells, some T cell 
lines (non-permissive cells) or in macrophages. 
 
CD4 as a primary receptor for HIV 1,3,5,41 
 
CD4 is a 58 kDa monomeric glycoprotein that can be detected on 
the cell surface of about 60 % of T-lymphocytes, on T-cell precursors 
within the bone marrow and thymus, and on monocytes and 
macrophages, eosinophils, dendritic cells and microglial cells of the 
central nervous system. The extracellular domain of the CD4 on T-cells 
is composed of 370 amino acids; the hydrophobic transmembrane 
domain and the cytoplasmic part of CD4 on T-cells consist of 25 and 38 
amino acids, respectively.  
 
Within the extracellular part of CD4, four regions D1-D4 have 
been characterized that represent immunoglobulin-like domains. 
Residues within the V2 region of CD4 (amino acids 40-55) are 
important for the bonding of gp120 to CD4 and this region overlaps the 
part of the CD4 where its natural ligands, HLA class II molecules, bind.  
 
The identification of the gp120 binding site on the CD4 of CD4+ 
T-cells stimulated attempts to use soluble CD4 (sCD4) to neutralize the 
circulating virus in patients, the aim being the inhibition of viral spread 
(Schooley 1990).  
 
However it became evident, that even though laboratory viral 
isolates  were easily neutralized by sCD4,neutralization of primary 
patient-derived isolates had not been achieved. In contrast, sCD4 was 
able to induce conformational changes within the viral envelope that 
promoted the infection of target cells (Bour 1995). CD4 attaches to the 
T cell receptor complex (TCR) on CD4+ T-cells and binds to HLA class 
II molecules on antigen-presenting cells.  
 
The binding of gp120 to CD4 is not only a crucial step for viral 
entry, but also interferes with intracellular signal transduction 
pathways and promotes apoptosis in CD4+ T-cells (Banda 1992). 
 
The apparent specificity of CD4
+ 
cell infection observed initially, 
together with the observation that T4 cells are those that are depleted in 
disease (indeed, the course of disease in the patient is followed by CD4
+ 
cell levels), suggested that CD4 antigen might be the receptor for the 
virus. This was demonstrated by transfecting CD4 antigen gene into 
CD4
- 
human cells and showing that they acquired the property of being 
able to be infected by HIV.  
  
 
 
 
 
 
 
Postfusion events 2,3,5 
 
Following membrane fusion the virus core uncoats into the 
cytoplasm of the target cell. The conversion of viral RNA into proviral 
DNA, mediated by the viral enzyme reverse transcriptase (RT), occurs 
in the cytoplasm of the target cell and is a crucial step within the viral 
replication cycle 
 
Blockade of the RT by the nucleoside inhibitor zidovudine was 
the first attempt to inhibit viral replication in HIV-1 infected patients. 
Reverse transcription occurs in multiple steps. After binding of the 
tRNA primers, synthesis of proviral DNA occurs as a minus-strand 
polymerization starting at the PBS (.primer binding site.) and extending 
up to the 5. repeat region as a short R/U5 DNA. The next step includes 
degradation of RNA above the PBS by the viral enzyme RNAase H and 
a .template switch. of the R/U5 DNA with hybridization of the R 
sequence at the RNA end.  
 
Now the full length polymerization of proviral DNA with 
degradation of the tRNA is completed. Reverse transcription results in 
double-stranded HIV DNA with LTR regions (.long terminal repeats.) 
at each end. However, cellular activation is necessary for integration of 
the proviral HIV DNA into the host cell genome after transportation of 
the pre-integration complex into the nucleus. Since natural HIV-1 
infection is characterized by continuing cycles of viral replication in 
activated CD4+ T-cells, viral latency in these resting CD4+ T-cells likely 
represents an accidental phenomenon and is not likely to be important 
in the pathogenesis of this disease.  
This small reservoir of latent provirus in quiescent CD4+ T-cells 
gains importance, however, in individuals who are treated with 
HAART, since the antivirals are unable to affect non-replicating 
proviruses and thus the virus will persist in those cells Macrophages, 
and activated and quiescent CD4+ T-cells are the main targets of 
infection.  
 
Permanent viral reservoirs, mainly in macrophages and latently 
infected CD4+ T-cells, are established in the early phase of infection 
and probably represent the major obstacle so far to successful 
eradication of HIV. 
 
During the whole course of infection with HIV-1, the lymphoid 
tissue represents the principle site of HIV-1 replication. The close cell-
cell contact between CD4+ T-cells and antigen-presenting cells, the 
presence of infectious virions on the surface of the FDC, and an  
abundant production of proinflammatory cytokines such as IL-1, IL-6 
or TNFα promotes the induction of viral replication in infected cells  
 
THE COURSE OF AIDS DISEASE  
 
a) Acute infection  
 
Initially, in the period immediately after infection, virus titer rises 
and the patient sometimes experiences some mononucleosis-like 
symptoms (fever, rash, swollen lymph glands). The result is an initial 
fall in the number of CD4
+ 
cells and a rise in CD8
+ 
cells but the numbers 
quickly return to normal 27. Macrophages are also infected; indeed, if 
acquired sexually, HIV at this stage if usually macrophage-tropic.  
 
 b) A strong anti-HIV immune defense  
 
Cytotoxic B and T lymphocytes mount a strong defense and virus 
is greatly reduced in the circulation. During this period, more than 10 
billion new HIV particles are produced each day but they are rapidly 
cleared. There can be up to 10
2 
to 10
7 
virus particles per ml of blood. 
Most of this virus is coming from recently infected proliferating CD4
+ 
cells. The infected cells that are producing this virus are destroyed 
either by the immune system or by the virus.  
 
However, the rate of production of CD4
+ 
cells can compensate for 
the loss of cells. Most CD4
+ 
cells at this stage are uninfected. This is the 
most infectious phase of the disease. Sero conversion occurs between 
one and four weeks after infection 36. 
 
c) A latent reservoir. 
 
 Although mainly cleared from the blood, the virus persists 
elsewhere such as in the lymph nodes, especially in association with 
dendritic cells. A small fraction of the productively infected CD4
+ 
cells 
may survive long enough to revert back to the resting memory state (as 
do non-infected CD4
+ 
memory cells). These carry a copy of the HIV 
genome, which remains latent until the cells are reactivated by  
antigen. These memory cells have a great potential for stability and 
constitute a reservoir that may be very important in drug-based 
therapy.  
 Although the number of HIV particles in the bloodstream falls 
during clinical latency, the virus is detectable. After the initial peak of 
virus, the virus reaches a "set point" during latency. This set point 
predicts the time of onset of clinical disease. With less than 1000 
copies/ml of blood, disease will probably occur with a latency period of 
more than 10 years. With fewer than 200 copies/ml, disease does not 
appear to occur at all 1. Most patients with more than 100,000 copies per 
ml, lose their CD4+ cells more rapidly and progress to AIDS before 10 
years. Most patients have between 10,000 and 100,000 copies per ml in 
the clinical latency phase (unless treated chemotherapeutically).  
 
d) Loss of CD4
+ 
cells and loss of the immune response. 
 
 The major reason that the immune system fails to control HIV 
infection is that the CD4
+ 
T helper cells are the target of the virus. Also 
dendritic cells present antigen to CD4
+ 
cells and may bring the virus 
into contact with these cells at the time that they are stimulated to 
proliferate by antigen 3,5. There is a relentless decline of CD4
+ 
cells with 
especially a loss of those specific to HIV, which occurs from the very 
beginning of infection and is permanent. Near the end stage of AIDS 
CD8
+ 
cells also decline precipitously.  
 
e) Onset of AIDS.  
 
Eventually, the virus can no longer be controlled as the virus and 
cytotoxic T (CD8
+
) cells destroy helper (T4) cells.  
 As the T4 cells fall below 200 per cu mm, virus titers rise rapidly 
and immune activity falls off. It is the loss of immune competence that 
enables normally benign parasites such as fungi or protozoa to cause 
disease. Once AIDS develops, patients rarely survive more than two 
years without chemotherapeutic intervention. There is considerable 
variability at this stage. Some patients with clinical AIDS do survive for 
several years while others who appear relatively healthy can suddenly 
succumb to a major opportunistic infection. The patients die from 
opportunistic infections. It is the onset of HIV-associated neoplasm and 
opportunistic infections that defines AIDS properly.  
 
A phase of HIV infection, AIDS-related complex (ARC), used to 
be defined. This is now little used. It is the phase of disease that lacks 
the neoplasms and opportunistic infections that are the definition of 
AIDS 58. Patients at this stage of the disease show weight loss and fatigue 
together with fungal infections of the mouth, finger and toe nails  
 
Patients undergoing HAART demonstrate a dramatic decrease in 
the number of productively infected CD4+ T cells within the lymphoid 
tissue (Tenner-Racz 1998).During the natural course of HIV-1 disease, 
the number of CD4+ T-cells slowly decreases while plasma viremia rises 
in most patients. 
 
Rosenberg and his group were able to demonstrate that initiation 
of HAART during primary HIV infection was associated with 
persistence of an HIV-specific CD4+ Tcell response that was not 
detected in patients analyzed during the chronic stage of disease 
(Rosenberg 1997). 
  
Recent studies of subjects infected with human immunodeficiency 
virus (HIV-1) have produced conflicting results about the extent of 
reconstitution possible in the CD4+ lymphocyte repertoire after highly 
active antiretroviral therapy 1,3 (HAART).  
 
The effect of HAART on the incidence of opportunistic infections 
will probably depend on reconstitution of antigen-specific CD4+ 
lymphocyte responses to important pathogens, including 
cytomegalovirus (CMV), the leading cause of blindness in AIDS 4,6. 
Several studies have demonstrated an important role for CD4+ 
lymphocytes in controlling CMV replication in vitro and in clinical 
studies 7,13.  
 
It is now possible to quantitate antigen-specific CD4+ lymphocyte 
responses by flow cytometry 14. Using this method, we studied CMV- 
specific CD4+ lymphocyte responses in individuals infected with HIV-1 
with and without a history of active CMV-associated end organ disease 
(EOD), and in those with quiescent CMV EOD after ganciclovir 
therapy and HAART. The presence of active CMV-associated EOD 
strongly correlated with loss of CMV-specific lymphocyte responses (P 
= 0.0004).  
 
In contrast, patients with no history of CMV-associated EOD and 
most patients with quiescent EOD after HAART demonstrated strong 
CMV-specific CD4+ lymphocyte responses.  
 
 
These data indicate that the loss of CMV-specific CD4+ 
lymphocyte responses in individuals infected with HIV-1 who have 
active CMV EOD may be restored after ganciclovir therapy and 
HAART, which provides evidence for functional immune reconstitution 
to an important pathogen. 
 
Highly active antiretroviral therapy (HAART) increases CD4(+) 
cell numbers, but its ability to correct the human immunodeficiency 
virus (HIV)-induced immune deficiency remains unknown. A three-
phase T cell reconstitution was demonstrated after HAART, with: (i) an 
early rise of memory CD4(+) cells, (ii) a reduction in T cell activation 
correlated to the decreasing retroviral activity together with an 
improved CD4(+) T cell reactivity to recall antigens, and (iii) a late rise 
of "naive" CD4(+) lymphocytes while CD8(+) T cells declined, however, 
without complete normalization of these parameters 25,47. Thus, 
decreasing the HIV load can reverse HIV-driven activation and CD4(+) 
T cell defects in advanced HIV-infected patients. 
 
A study was conducted and revealed the proportion of patients 
with CD4 cell counts <50 cells × 106/l decreased in response to HAART 
and the rate of change was greatest between 1 and 3 months after 
commencing treatment . However, the reduction in patients with a 
detectable HIV viral load was seen almost immediately after the start of 
HAART This trend tapers out around 9 months for CD4 counts and 
around 3 months for HIV viral load measurements. The above changes 
demonstrate a good response to treatment although some patients have 
persistently low CD4 cell counts and detectable HIV viral load 33,26 . 
From a clinical standpoint, only five AE were observed during the 
second year of follow up and none during the last year of follow up , 
indicating significant clinical immunorestoration beyond 12-18 months 
for all patients. Other clinical and laboratory studies also suggest 
significant immunorestoration to CMV in response to HAART. Some 
patients, however, have a persistently low CD4 cell count (<20) 
following triple therapy and may remain at relatively high risk of 
developing AIDS diseases. It would therefore seem logical to monitor 
closely patients with very low CD4 counts after PI initiation and to 
continue with anti-CMV therapy until CD4 cell counts have been 
greater than 100 for at least 6 months.  
HAART 
 
The development of antiretroviral therapy has been one of the 
most dramatic progressions in the history of medicine. Zidovudine was 
first tested on humans in 1985, and introduced as a treatment in March 
1987 with great expectations 19,47.  
 
Initially, at least, it did not seem to be very effective. The same 
was true for the nucleoside analogs zalcitabine, didanosine and 
stavudine, introduced between 1991 and 1994. 
 
Then, in September 1995, the preliminary results of the 
European-Australian DELTA Study (Delta 1995) and the American 
ACTG 175 Study (Hammer 1996) attracted attention. It became 
apparent that combination therapy with two nucleoside analogs was 
more effective than monotherapy. All these efforts led to a fast track 
approval, between December 1995 and March 1996, for all three PIs . 
first saquinavir, followed by ritonavir and indinavir . for the treatment 
of HIV. HAART  began to spread irreversibly. 
 By June 1996, the first non-nucleoside reverse transcriptase 
inhibitor, nevirapine, was licensed, and a third drug class introduced. 
Nelfinavir, another PI, also arrived.  
 
Antiretroviral agents 13,28,29,30 
 
Several distinct classes of drugs are now used in combination to 
treat HIV infection, commonly referred to as HAART, "Highly Active 
Antiretroviral Therapy”  
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTI). 
These drugs inhibit viral RNA-dependent DNA polymerase (reverse 
transcriptase) and are incorporated into viral DNA (they are chain-
terminating drugs).  
Zidovudine (AZT = ZDV) first approved in 1987  
Didanosine (ddI)  
Zalcitabine (ddC)  
Stavudine (d4T)  
Lamivudine (3TC)  
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). 
In contrast to NRTIs, NNRTIs are not incorporated into viral DNA; 
they inhibit HIV replication directly by binding non-competitively to 
reverse transcriptase.  
Nevirapine , Delavirdine  
Protease Inhibitors. These drugs are specific for the HIV-1 
protease and competitively inhibit the enzyme, preventing the 
maturation of virions capable of infecting other cells, e.g:  
Saquinavir first approved in 1995  
Ritonavir   
Indinavir   
Nelfinavir   
Abacavir 
 
Clinical categories  in HIV-infected persons 11 
 
Category A 
 
Asymptomatic HIV infection 
Acute (primary) HIV infection with accompanying 
illness or history of acute HIV infection 
Persistent generalized lymphadenopathy 
 
Category B 
 
Symptomatic conditions* that are not included 
among conditions listed in clinical Category C.  
Examples include, but are not limited to: 
Bacillary angiomatosis 
Candidiasis, oropharyngeal (thrush) 
Candidiasis, vulvovaginal; persistent, 
frequent, or poorly responsive to therapy 
Cervical dysplasia (moderate or severe)/ 
cervical carcinoma in situ 
Constitutional symptoms, such as fever 
(38.5° C) or diarrhea lasting longer than 
1 month 
Hairy leukoplakia, oral 
Herpes zoster (shingles), involving at least 
two distinct episodes or more than one 
dermatome 
Idiopathic thrombocytopenic purpura 
Listeriosis 
Pelvic inflammatory disease, particularly if 
complicated by tubo-ovarian abscess 
Peripheral neuropathy 
 
Category C - AIDS-defining illnesses** 
 
Candidiasis of bronchi, trachea, or lungs 
Candidiasis, esophageal 
Cervical cancer, invasive* 
Coccidioidomycosis, disseminated or extrapulmonary 
Cryptococcosis, extrapulmonary 
Cryptosporidiosis, chronic intestinal (greater 
than 1 month’s duration) 
Cytomegalovirus disease (other than liver, 
spleen, or nodes) 
Cytomegalovirus retinitis (with loss of vision) 
Encephalopathy, HIV-related 
Herpes simplex: chronic ulcer(s) (greater 
than 1 month’s duration); or bronchitis, 
pneumonitis, or esophagitis 
Histoplasmosis, disseminated or extrapulmonary 
Isosporiasis, chronic intestinal (greater than 
1 month’s duration) 
Kaposi’s sarcoma 
Lymphoma, Burkitt’s (or equivalent term) 
Lymphoma, immunoblastic (or equivalent) 
Lymphoma, primary, of brain 
Mycobacterium avium complex or M. kansasii, 
disseminated or extrapulmonary 
Mycobacterium tuberculosis, any site (pulmonary 
or extrapulmonary) 
Mycobacterium, other species or unidentified 
species, disseminated or extrapulmonary 
Pneumocystis pneumonia 
Pneumonia, recurrent* 
Progressive multifocal leukoencephalopathy 
Salmonella septicemia, recurrent 
Toxoplasmosis of brain 
Wasting syndrome due to HIV 
 
 
 
 
 
 
The Retroviral agents that are used in this study are 
Stauvudine 
Lamivudine 
Nevirapine 
Efavirenz 
Zidovudine 
 
The combinations of these drugs are used as HAART therapy in this 
study.They are; 
 
A.  d4T 30 + 3TC + NVP 
B.  d4T 40 + 3TC + NVP 
C.  d4T 30 + 3TC + EFV 
D.  d4T 40 + 3TC + EFV 
E.  ZDV + 3TC + NVP 
F.  ZDV + 3TC + EFV 
 
The choice of combinations are based on the disease presentation, 
emergence of toxicity or side effects, treatment failure, concurrent 
administration of other drugs which interfere with the metabolism and 
compliance of the patient. 
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MATERIALS AND METHODS 
 
 
This study was conducted on the patients who attended the ART 
centre at Tirunelveli Medical College  between the period October 2005 
and August 2006. The study population consist of all patients with 
Adult HIV Disease (according to World Health Organisation 
classification criteria). Patients taking anti-tuberculous drugs are also 
included in the study. Children are not included in the study. 
 
A total of 58 patients were registered for the study but two of 
them died during the course of therapy. The net total number of 
subjects are 56. Among them 43 were males and 13 were females. 
 
A chart was prepared with details regarding initial CD4 count, 
follow up CD4 count, oppurtunistic infections at the time of 
presentation, type of HAART therapy and the pre and post therapy 
body weight. 
 
The diagnosis of AIDS  was made using WHO criteria for Adult 
HIV disease and ELISA test for HIV I&II. 
 
The presence of opportunistic infections were not considered to be 
interfering with the study and infact they served as prognostic 
indicators for the HAART. 
 
  The initial and follow up CD4 counts were done at atleast six 
months interval. 
  
 
Statistical analysis: 
 
The results are inferred on the basis of statistical tools viz., ‘Z’ 
test and students ‘t’ test. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION    AND   RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION AND RESULTS 
 
 
 
This study was conducted on the patients who attended the ART 
centre at Tirunelveli Medical College  between the period October 2005 
and August 2006.The study was a prospective study. A total of 56 
patients were studied 
 
Out of the 56, 43 are males and 13 were females 
 
Age Group Male Female Total 
20- 29 5 3 8 
30- 39 23 8 31 
40 – 49 8 0 8 
50- 59 5 2 7 
60- 69 2 0 2 
Total 43 13 56 
Mean 39.4 35.8 38.6 
S.D 10.1 9.5 10.0 
Z 1.17  
Significance P > 0.05  
 
The mean age of male patients were 39.4 +/-10.1 and the mean age 
of female patients were 35.8 +/- 9.5. The mean age of the total study 
population is 38.6 +/- 10. This table shows that the mean age of male 
and female sub groups were comparable and the difference is not 
statistically significant 
 
 
Comparative analysis of the initial and follow up CD4 
count in male subjects 
 
 
 
Male  
CD4 count Initial Followup
0-100 21 4 
100-200 14 7 
200-300 4 12 
300-400 2 12 
400-500 2 4 
500-600 0 2 
600-700 0 2 
700-800 0 0 
Total 43 43 
Mean 133.7 294.2 
S.D 108.9 148.5 
Z 5.7 
Significance P < 0.0001 
 
 
 
In the male subgroup the mean CD4 count at the time of 
presentation is 133.7 and the mean CD4 count after follow up is 294.2.In 
this table the mean CD4 count before and after therapy were compared 
and the difference is statistically significant (P < 0.0001) 
 
 
 
 
 
 
 
 
 
 
 
 
Comparative analysis of the initial and follow up CD4 
count in female subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the female subgroup the mean CD4 count at the time of 
presentation is 126.9 and the mean CD4 count after followup is 373.1.In 
this table the mean CD4 count before and after therapy were compared 
and the difference is statistically significant  
(P < 0.01) 
 
 
 
 
 
 
 
Female CD4 count 
Initial Followup
0-100 8 1 
100-200 3 1 
200-300 1 3 
300-400 0 4 
400-500 0 0 
500-600 1 2 
600-700 0 1 
700-800 0 1 
Total 13 13 
Mean 126.9 373.1 
S.D 142.3 200.6 
T 3.609 
Significance P < 0.01 
 
 
 
Comparative analysis of the initial and follow up CD4 
count in total subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In total, the mean CD4 count at the time of presentation is 132.1 
and the mean CD4 count after followup is 312.5.In this table the mean 
CD4 count before and after therapy were compared and the difference 
is statistically significant (P < 0.0001) 
 
 
 
 
 
 
 
Total CD4 count 
Initial Folloup 
0-100 29 5 
100-200 17 8 
200-300 5 15 
300-400 2 16 
400-500 2 4 
500-600 1 4 
600-700 0 3 
700-800 0 1 
Total 56 56 
Mean 132.1 312.5 
S.D 116.2 163.5 
Z 6.7 
Significance P < 0.0001 
 
 
Bar diagram showing Initial CD4 count in males 
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Bar diagram showing follow up CD4 count in males 
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Bar diagram showing Initial CD4 count in females 
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Bar diagram showing follow up CD4 count in females 
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Comparison of change in CD4 count before and after 
HAART in males 
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Comparison of change in CD4 count before and after 
HAART in females 
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Comparison of change in CD4 count before and after 
HAART in total subjects 
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DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
The Current study aimed at finding the correlation between CD4 
count and HAART  and the change in CD4 count after HAART. 
However there were  sex related change in the subjects with respect to 
age. The change in CD4 count in the total subjects without doubt has 
been noticed. The difference between the male and female subjects was 
not statistically significant and the overall increase is seen in both sexes. 
Most of the previous studies evaluated the increase in CD4 count 
with relation to sex and also to viral load. With the available resources 
the study involves both the sex correlation and independently. 
Most of the patients seeking medical therapy fall in a range of low 
CD4 count between 0 – 100.The clinical and epidemiological importance 
of this finding is important for the patients and therapists. 
The clinical importance of HAART is related to its impact on the 
CD4 count as well as the well being of the patient. 
In this study it was found that the  mean age of seeking medical advice 
is between 36.1 – 41.1 years. 
There is no sex difference in presentation of the disease  
(p > 0.05) .The reason for this could be due to the disease awareness in 
both the sexes. Another cause that can be attributed could be the down 
regulation of the immune system with advancing age and the subjects 
above 50 year age group are low in number when compared to younger 
age groups.  
 
 
From the statistics it understood that the mean CD4 count at the 
time of presentation was 133.7 in males and 126.9 in females. This when  
compared to the normal CD4 count is much less. It is also noted the 
subjects presenting with a very low count initially , after HAART show  
improvment in the CD4 count and the magnitude of the opportunistic 
infections. 
  The mean increase of the count when the total subjects are taken 
is also significant ( Z – 6.7 ). The mean count after therapy was 294.2 in 
males and 373.1 in females. There is a moderate difference in the 
increase of cells between the sexes can be noted.  
Even though the initial count is very low in females when compared to 
males the response to HAART is good for females than in males. The 
males also show a rise in count but not to the extent of females. 
Castagna et al in their study showed that sopping HAART resulted in 
gradual decline in the number of CD4 cells. However this study does not 
include the individuality of antiretroviral drugs. The drugs used are 
combinations of individual agents. 
While analysing the data it can be known that  the number of 
subjects in the 0 -100 CD4 count group initially showed good response 
to therapy. 
There are also decline in the number of cells in few subjects. It 
can be noted that these subjects presented with very low CD4 count at 
the beginning. 
These findings show the definitive impact of HAART in 
increasing CD4 cells in AIDS patients. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
Majority of the AIDS patients present with a low CD4 count 
especially the females. 
 
The females show a dramatic improvement in the CD4 count 
after HAART when compared to males eventhough they present with a 
very low count initially 
 
The mean age of presentation of the disease for both males and 
females is around 37 years 
 
There is a definite increase in the CD4 cell count after initiation of 
HAART. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS  OF  THE  STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS OF THE STUDY 
 
 
 
This study does not take into account the existence of the  
opportunistic infections at the time of presentation and in the course of 
therapy. 
 
This study does not include children. 
 
The study does not include the change in CD4 counts within six 
months after institution of HAART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
 
 
The presentation of AIDS occurs commonly in the middle age 
group. The females are presenting with a very low CD4 count initially. 
However the response to HAART is much higher in females than in 
males and above all that the institution of HAART has major influence 
on CD4 counts by increasing the number. The counts increase from an 
abnormal low level to acceptable levels. 
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